COMMUNIQUÉS West-GlobeNewswire

MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach
10/12/2025
CHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology (NYSE American: MAIA) – The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a decade of targeted [...]
Carrick Therapeutics Announces Positive Results from Phase 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer
10/12/2025
Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene mutation Phase 2 results presented at 2025 San Antonio Breast Cancer Symposium BOSTON, Dec. 10, 2025 ( [...]
Tiny Health Celebrates 100,000 Tests Milestone, Expands from Baby Gut Health Pioneer to Longevity Innovator
10/12/2025
The microbiome startup powering preventive and personalized health launches new aging study and deepens partnerships with leading wellness and longevity programs AUSTIN, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Tiny [...]
Persephone Biosciences Announces Publication in Cell Host & Microbe Highlighting the Critical Need to Restore Bifidobacterium in the Infant Gut Microbiome
10/12/2025
- Evidence shows infant microbiome trajectories established in the first months of life persist, shaping immune function and allergy risk into childhood - - Targeted early-life probiotic interventions using B. infantis [...]
EssilorLuxottica joins forces with Fondazione Chips-IT to accelerate the future of smart eyewear
10/12/2025
EssilorLuxottica joins forces with Fondazione Chips-IT to accelerate the future of smart eyewear Paris, France (10 December 2025) – EssilorLuxottica announces it is joining forces with Fondazione Chips-IT, Italy’s [...]
EssilorLuxottica va collaborer avec la fondation Chips-IT pour accélérer dans les lunettes connectées
10/12/2025
EssilorLuxottica va collaborer avec la fondation Chips-IT pour accélérer dans les lunettes connectées Paris, France (10 décembre 2025) – EssilorLuxottica a annoncé aujourd'hui une collaboration avec la fondation Chips- [...]
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy
10/12/2025
Highly encouraging early data from the ongoing Phase 1b study evaluating investigational drug GNS561 with a MEK inhibitor (MEKi) in KRAS mutated cholangiocarcinoma (CCA), positioning this novel combination as a [...]
GENFIT : GNS561 montre une activité antitumorale prometteuse en combinaison thérapeutique
10/12/2025
Données préliminaires très encourageantes de l’étude de Phase 1b en cours évaluant le médicament expérimental GNS561 associé à un inhibiteur de MEK (MEKi) dans le cholangiocarcinome (CCA) avec mutation KRAS, [...]
Tristan Imbert co-opted as Independent Director
10/12/2025
Press Release Paris – December 10, 2025 - EUROAPI today announces that, following the resignation of Rodolfo Savitzky from his position as Independent Director (effective December 31, 2025) 1 , and upon the [...]
Tristan Imbert coopté Administrateur Indépendant
10/12/2025
Communiqué de presse Paris - Le 10 décembre 2025 - EUROAPI annonce aujourd’hui qu’à la suite de la démission de Rodolfo Savitzky de son poste d’Administrateur Indépendant (effective au 31 décembre 2025) 1 et sur [...]
Bioxodes raises €5.5 million Series A extension to continue preparations for pivotal trial of breakthrough stroke candidate
10/12/2025
Newton Biocapital enters as new investor, strong participation of existing investors Pivotal Phase 2b trial initiation in 2027 of BIOX-101 to treat intracerebral hemorrhage BIOX-101 may be commercialized as early as H2 [...]
Bioxodes lève 5,5 millions d'euros dans le cadre d'une extension de la Série A afin de poursuivre la préparation d’un essai pivot pour son candidat-médicament innovant dans le traitement de l'AVC
10/12/2025
Newton Biocapital entre au capital en tant que nouvel investisseur, importante participation des investisseurs historiques Lancement en 2027 d’un essai pivot de phase 2b portant sur BIOX-101 dans le traitement de l’AVC [...]
Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer
10/12/2025
Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targets The agreement - OBT's second high-profile pharma collaboration [...]
New Hypertension publication underscores aprocitentan’s potential in managing hypertension patients with CKD
10/12/2025
New analysis from landmark Phase 3 PRECISION trial published in Hypertension highlights the renal-protective benefits of aprocitentan in addition to the marked reduction in blood pressure in a high-risk CKD population [...]
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
10/12/2025
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price [...]
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering
10/12/2025
WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Terns Announces Pricing of Upsized $650 Million Public Offering
10/12/2025
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten [...]
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
10/12/2025
SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, [...]
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
10/12/2025
CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“ [...]

Pages